Seasoned Entrepreneurs Examples
Carol Nacy
Dr. Carol A. Nacy is currently founder and Chief Executive Officer of Sequella, Inc., a fifteen year- old privately-held pharmaceutical company that commercializes new and more effective treatments for life-threatening infectious diseases. Sequella has a novel antibiotic in a pivotal trial in Russia for MDR-TB with its corporate partner Infectex, a Phase 2 efficacy study in Africa in drug-sensitive TB, and a Phase 2 efficacy study in Texas for Helicobacter pylori infections. Sequella also has an extensive pipeline of earlier-stage drugs moving to the clinic in various infectious disease indications. Sequella has ongoing research collaborations with large pharmaceutical companies and academic centers for development of new drugs for neglected diseases. Sequella raised $81M to date from institutional and individual investors and peer- reviewed grants. Prior to Sequella, Dr. Nacy was Executive Vice President and Chief Scientific Officer at EntreMed, Inc., from 1993 through its successful public offering in June 1996. She left EntreMed in November 1996 to establish Sequella, Inc. and was part-time Chief Scientific Officer (1997-1998) for Anergen, Inc., a California company focused on autoimmune diseases. There, she reorganized the scientific staff and positioned the company for acquisition by Corixa Corp. in December 1998. Dr. Nacy became full time CEO and Chair of the Board of Sequella in January 1999. She is a member of the Board of Directors of for-profit companies (Social and Scientific Systems) and non-profit agencies (Sequella Foundation, Tech Council of Maryland, Foundation for Soldier and World Health, among others) and on a number of committees in global health organizations. Prior to her business experience, Dr. Nacy was career scientist and science manager for 17 years at the Walter Reed Army Institute of Research in Washington, DC, where she studied tropical infectious diseases. She has published over 160 scientific papers to date. Dr. Nacy was elected to the American Academy of Microbiology in 1985. She maintains strong ties to the scientific research community, was President of the American Society for Microbiology (1996) and the Society for Leukocyte Biology (1993), and was on the Board of the National Academy of Science, National Research Council (1996-2001). She is an adjunct faculty member of both the Department of Biology at the Catholic University of America, and the Department of Tropical Diseases at the George Washington University, Washington, DC. She earned her A.B., M.S., and Ph.D. degrees from the Catholic University of America in Washington, DC: in 2002 she was awarded a Lifetime Achievement Award in Science from CUA. Dr. Nacy was singled out as a Top 50 Innovator in the U.S. by Inc. Magazine in 2002, named Entrepreneur of the Year by Women in BIO in 2004. The state of Maryland named Dr. Nacy in its Top 100 Business Women in 2005, and the Washington Business Journal named her as a top 25 female executive in the Washington DC metropolitan area in 2005. In 2006, she received a National Leadership Award in Healthcare from the National Urban Technology Center in New York City, and in 2007 she was honored with a Special Outstanding Achievement Award for Clinical Trials by Women in BIO. In December 2009 she was awarded the Humanitarian Award, Hope is a Vaccine, by the Global Alliance for Immunization against Aids (GAIA) for her work to create new drugs for TB
Gil Price
Dr. Gil Price is a clinical physician trained in Internal Medicine with a long-standing interest in the study of adverse drug reactions, drug utilization, drug development and regulation. He is an accomplished senior level manager with over 26 years of diverse therapeutic drug development experience. His responsibilities have included pharmacovigilance, competitive intelligence, and clinical development. Prior to his current position as Founder and CEO of Drug Safety Solutions, Dr. Price was the Director of Clinical Development for Oncology at MedImmune Inc. He previously worked in the CRO sector at ClinTrials. Dr. Price began his pharmaceutical career at Glaxo, Inc. in Research Triangle Park, NC, where he worked for nearly nine years on both the commercial and research sides of the company. Dr. Price is a member of the American Medical Association, the Academy of Pharmaceutical Physicians, the American Society of Microbiology, the Association of Clinical Research Professionals, and the Drug Information Association
Dr. Carol A. Nacy is currently founder and Chief Executive Officer of Sequella, Inc., a fifteen year- old privately-held pharmaceutical company that commercializes new and more effective treatments for life-threatening infectious diseases. Sequella has a novel antibiotic in a pivotal trial in Russia for MDR-TB with its corporate partner Infectex, a Phase 2 efficacy study in Africa in drug-sensitive TB, and a Phase 2 efficacy study in Texas for Helicobacter pylori infections. Sequella also has an extensive pipeline of earlier-stage drugs moving to the clinic in various infectious disease indications. Sequella has ongoing research collaborations with large pharmaceutical companies and academic centers for development of new drugs for neglected diseases. Sequella raised $81M to date from institutional and individual investors and peer- reviewed grants. Prior to Sequella, Dr. Nacy was Executive Vice President and Chief Scientific Officer at EntreMed, Inc., from 1993 through its successful public offering in June 1996. She left EntreMed in November 1996 to establish Sequella, Inc. and was part-time Chief Scientific Officer (1997-1998) for Anergen, Inc., a California company focused on autoimmune diseases. There, she reorganized the scientific staff and positioned the company for acquisition by Corixa Corp. in December 1998. Dr. Nacy became full time CEO and Chair of the Board of Sequella in January 1999. She is a member of the Board of Directors of for-profit companies (Social and Scientific Systems) and non-profit agencies (Sequella Foundation, Tech Council of Maryland, Foundation for Soldier and World Health, among others) and on a number of committees in global health organizations. Prior to her business experience, Dr. Nacy was career scientist and science manager for 17 years at the Walter Reed Army Institute of Research in Washington, DC, where she studied tropical infectious diseases. She has published over 160 scientific papers to date. Dr. Nacy was elected to the American Academy of Microbiology in 1985. She maintains strong ties to the scientific research community, was President of the American Society for Microbiology (1996) and the Society for Leukocyte Biology (1993), and was on the Board of the National Academy of Science, National Research Council (1996-2001). She is an adjunct faculty member of both the Department of Biology at the Catholic University of America, and the Department of Tropical Diseases at the George Washington University, Washington, DC. She earned her A.B., M.S., and Ph.D. degrees from the Catholic University of America in Washington, DC: in 2002 she was awarded a Lifetime Achievement Award in Science from CUA. Dr. Nacy was singled out as a Top 50 Innovator in the U.S. by Inc. Magazine in 2002, named Entrepreneur of the Year by Women in BIO in 2004. The state of Maryland named Dr. Nacy in its Top 100 Business Women in 2005, and the Washington Business Journal named her as a top 25 female executive in the Washington DC metropolitan area in 2005. In 2006, she received a National Leadership Award in Healthcare from the National Urban Technology Center in New York City, and in 2007 she was honored with a Special Outstanding Achievement Award for Clinical Trials by Women in BIO. In December 2009 she was awarded the Humanitarian Award, Hope is a Vaccine, by the Global Alliance for Immunization against Aids (GAIA) for her work to create new drugs for TB
Gil Price
Dr. Gil Price is a clinical physician trained in Internal Medicine with a long-standing interest in the study of adverse drug reactions, drug utilization, drug development and regulation. He is an accomplished senior level manager with over 26 years of diverse therapeutic drug development experience. His responsibilities have included pharmacovigilance, competitive intelligence, and clinical development. Prior to his current position as Founder and CEO of Drug Safety Solutions, Dr. Price was the Director of Clinical Development for Oncology at MedImmune Inc. He previously worked in the CRO sector at ClinTrials. Dr. Price began his pharmaceutical career at Glaxo, Inc. in Research Triangle Park, NC, where he worked for nearly nine years on both the commercial and research sides of the company. Dr. Price is a member of the American Medical Association, the Academy of Pharmaceutical Physicians, the American Society of Microbiology, the Association of Clinical Research Professionals, and the Drug Information Association
